http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Dare Bioscience (DARE) Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
-
Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
-
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
-
Dare Bioscience (DARE) Announces Positive Topline Results from DARE-VVA1 Study
-
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
-
Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
-
Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
-
Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
-
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
-
Dare Bioscience (DARE) Reports Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
-
Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
-
Dare Bioscience (DARE) Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovapren
-
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
-
Daré Bioscience to Participate in Two Upcoming Conferences
-
Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference
-
Dare Bioscience (DARE) Reports Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream
-
Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
-
Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
-
Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update
-
Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022
-
Daré Bioscience to Participate in Maxim Group Women’s Health Panel
-
Dare Bioscience (DARE) Announces Closing of Global License Agreement with Organon to Commercialize XACIATO, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
-
Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Ba
-
Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022
-
Daré Bioscience to Participate in the 2022 BIO International Convention
-
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
-
Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
-
Daré Bioscience Announces NIH Grant Award
-
Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022
-
Daré Bioscience to Participate in Upcoming Conference
-
Dare Bioscience (DARE) Initiates Phase 1/2 Clinical Study of DARE-HRT1
-
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
-
Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update
-
Organon (OGN) and Dare (DARE) Enter Agreement to Commercialize XACIATO
-
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Va
-
Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022
-
Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference
-
Daré Bioscience to Participate in Upcoming Conferences
-
Daré Bioscience to Participate in Upcoming Conferences
-
Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
-
Dare Bioscience (DARE) Confirms FDA Approval of XACIATO (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
-
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
-
Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update
-
Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
-
Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021
-
Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021
-
Dare Bioscience (DARE) Awarded NIH Grant for Development of DARE-LARC1
-
Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
-
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy
-
Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference
